Softwr

AI · head to head

LatchBio vs Seven Bridges

LatchBio logo

LatchBio

AI

AI agents that run bioinformatics analyses, from a company that pivoted from workflow hosting

From
On request
Rated
-
Full reviewWebsite
Seven Bridges logo

Seven Bridges

Research

Cloud bioinformatics platform and trusted research environment, sold by Velsera

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: LatchBio the company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.; Seven Bridges the parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
  • They diverge on capability: LatchBio covers Agent driven analysis, Seven Bridges covers Trusted research environment.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which LatchBio and Seven Bridges actually diverge.

Attributes where LatchBio and Seven Bridges differ
AttributeLatchBioSeven Bridges
PlatformsWebWeb, API, Cloud
CategoryAIResearch

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in LatchBio

  • Agent driven analysis
  • Multi assay support
  • Published benchmarks
  • White labelled portals
  • Common file format handling
  • Managed compute

Only in Seven Bridges

  • Trusted research environment
  • Cloud-agnostic
  • CWL pipelines
  • Compliance certifications
  • Cost prediction
  • Public data commons
  • Collaboration
  • Tool library

What people use each for

The jobs each tool is most often brought in to do.

LatchBio

  • A small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quicklynot Seven Bridges
  • An assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw filesnot Seven Bridges
  • A wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facilitynot Seven Bridges
  • A research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegatednot Seven Bridges

Seven Bridges

  • A cancer genomics group analysing controlled-access dbGaP data that cannot be moved to local infrastructurenot LatchBio
  • A federal or federally funded programme that needs FedRAMP Moderate authorisation for its analysis environmentnot LatchBio
  • A multi-institution consortium sharing pipelines and results under defined access controls rather than by emailing filesnot LatchBio
  • A diagnostics developer building reproducible CWL pipelines that must stand up to later regulatory reviewnot LatchBio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

LatchBio

  • The company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • Agent generated analysis code has to be validated by someone who could have written it, which inverts the value proposition for the small labs that most need it and cannot check the output.
  • No pricing is published, so the cost of routine agent analysis at team scale cannot be estimated without contacting sales, and compute billed through the platform makes the bill usage dependent.
  • Regulated use is a poor fit: an agent that writes non deterministic analysis code is difficult to validate under GxP, so this is a research tool rather than something that will sit in a regulated diagnostic or submission workflow.
  • The vendor publishes its own benchmarks, which is more than most competitors do, but self reported benchmarks on selected datasets are not a substitute for testing the agent on your own data before committing.

Seven Bridges

  • The parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
  • Pricing is not published and splits into a platform subscription plus consumption-based cloud compute, so a heavy analysis quarter produces a bill that headcount-based budgeting does not anticipate.
  • The analysis capability itself has credible open source equivalents in Nextflow and Cromwell on raw cloud, so you are principally paying for compliance and governance rather than for the science.
  • Pipelines are built around Common Workflow Language, which is a real learning curve and a portability commitment for teams whose existing work is in other workflow languages.
  • Cloud storage of large genomic datasets accrues continuously whether or not you are analysing, and egress charges apply when moving results out, both of which are outside the subscription line.

Pricing, plan by plan

LatchBio

On request
  • LatchBio Platform$undefined/year
    • Quoted through a sales process
    • Interactive sandbox available for trying the agent before contracting
    • Enterprise and white labelled portal deployments priced separately

Seven Bridges

On request
  • Seven Bridges Platform$undefined/year
    • Platform subscription quoted through Velsera sales
    • Cloud compute and storage charged on consumption on top of the subscription
    • Cost predictor tools provided to estimate analysis spend in advance

Which should you pick?

Choose LatchBio if

  • You need agent driven analysis.
  • You also want multi assay support.
LatchBio review

Choose Seven Bridges if

  • You need trusted research environment.
  • You work on Web, API, Cloud.
  • You also want cloud-agnostic.
Seven Bridges review

Questions people ask

Is LatchBio or Seven Bridges better?
Neither clearly leads. LatchBio starts at On request and Seven Bridges at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, LatchBio or Seven Bridges?
LatchBio starts at On request and Seven Bridges at On request.
Does LatchBio or Seven Bridges run on more platforms?
LatchBio runs on Web. Seven Bridges runs on Web, API, Cloud.
What is LatchBio best used for?
LatchBio is most often used for a small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quickly, an assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw files, a wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facility, a research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegated. Of those, a small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quickly and an assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw files are not what Seven Bridges is typically brought in for.
What can LatchBio do that Seven Bridges cannot?
LatchBio covers Agent driven analysis, Multi assay support, Published benchmarks, White labelled portals. Seven Bridges covers Trusted research environment, Cloud-agnostic, CWL pipelines, Compliance certifications.

Answered from the vendors’ own pages

LatchBio: Is LatchBio still selling the original workflow platform?

The company is now led by agent.bio and its agent products. Buyers evaluating the older Python SDK workflow platform should confirm current support directly.

Seven Bridges: Is Seven Bridges still sold?

Yes. It is sold by Velsera, formed in 2023 when Summa Equity merged Seven Bridges with Pierian and UgenTec. The Seven Bridges name was retained for the platform.

LatchBio: Can I try it before buying?

Yes. There is an interactive sandbox where you can upload data and run the agent before entering a sales conversation.

Seven Bridges: What compliance does it hold?

FedRAMP Moderate, SOC 2, HIPAA, GDPR, dbGaP and ISO 27001, 27017, 27018 and 27701, which is the usual reason institutions choose it over building on raw cloud.

LatchBio: Is it suitable for regulated work?

Not really. Non deterministic agent generated code is hard to validate under GxP, so treat it as a research and exploration tool.

Seven Bridges: How is it priced?

Not published. Expect a platform subscription plus consumption charges for cloud compute and storage.

LatchBio: What data types does it handle?

Single cell RNA sequencing, spatial transcriptomics, epigenomics, proteomics and pharmacology data, ingesting FastQ, H5AD and spreadsheet formats.

Seven Bridges: Do I have to use a specific cloud?

No. The platform is cloud-agnostic and designed to bring analysis to where the data already resides.

Share

Related pages

More on LatchBio

More on Seven Bridges

Keep looking

Other head to heads